VCA Stocks

Cempra Pharmaceuticals Inc. has raised $10 million in Series B funding.  Cempra is a biotechnology company founded to capture near-term value from market opportunities in antibiotics to meet urgent and continuing needs to treat drug-resistant bacteria in the hospital and community. The strategy is based on the pharmaceutical and biotechnology industry experience of Cempra’s founders and advisors in the areas of drug development and anti-infectives.  Cempra’s approach is to balance near-term product development opportunities including the macrolide CEM-101 (OP-1068), while investing in future products from new technologies to derive the next generation macrolides as well as other classes of antibiotics.